- Stocks
- Healthcare
- NASDAQ: DVAX

Price (delayed)

$13.7

Market cap

$1.77B

P/E Ratio

28.54

Dividend/share

N/A

EPS

$0.48

Enterprise value

$1.87B

Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. for prevention of

Dynavax Technologies's equity has increased by 21% YoY and by 4.8% from the previous quarter

DVAX's gross margin is up by 6% QoQ and by 3.7% YoY

DVAX's price to earnings (P/E) is 105% higher than its last 4 quarters average of 13.9

DVAX's EPS has plunged by 82% YoY and by 45% from the previous quarter

What are the main financial stats of DVAX

Market
Valuations
Earnings

Shares outstanding

129.26M

Market cap

$1.77B

Enterprise value

$1.87B

Price to earnings (P/E)

28.54

Price to book (P/B)

2.92

Price to sales (P/S)

4.89

EV/EBIT

26.95

EV/EBITDA

24.56

EV/Sales

5.18

Revenue

$361.18M

EBIT

$69.36M

EBITDA

$76.13M

Free cash flow

$118.78M

Per share
Balance sheet
Liquidity

EPS

$0.48

Free cash flow per share

$0.92

Book value per share

$4.7

Revenue per share

$2.8

TBVPS

$7.53

Total assets

$972.93M

Total liabilities

$368.02M

Debt

$253.1M

Equity

$604.92M

Working capital

$781.4M

Debt to equity

0.42

Current ratio

15.4

Quick ratio

14.14

Net debt/EBITDA

1.29

Margins
Efficiency
Dividend

EBITDA margin

21.1%

Gross margin

67.1%

Net margin

16.9%

Operating margin

9.6%

Return on assets

6.3%

Return on equity

10.5%

Return on invested capital

7.4%

Return on capital employed

7.6%

Return on sales

19.2%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Dynavax Technologies stock price performed over time

Intraday

2.47%

1 week

1.63%

1 month

-5.26%

1 year

10.39%

YTD

28.76%

QTD

-7.24%

How have Dynavax Technologies's revenue and profit performed over time

Revenue

$361.18M

Gross profit

$242.21M

Operating income

$34.6M

Net income

$61.13M

Gross margin

67.1%

Net margin

16.9%

DVAX's operating income has dropped by 89% year-on-year and by 62% since the previous quarter

The net income has dropped by 81% year-on-year and by 45% since the previous quarter

The company's operating margin has shrunk by 77% YoY and by 52% QoQ

Dynavax Technologies's net margin has plunged by 62% YoY and by 30% from the previous quarter

What is Dynavax Technologies's growth rate over time

What is Dynavax Technologies stock price valuation

P/E

28.54

P/B

2.92

P/S

4.89

EV/EBIT

26.95

EV/EBITDA

24.56

EV/Sales

5.18

DVAX's price to earnings (P/E) is 105% higher than its last 4 quarters average of 13.9

DVAX's EPS has plunged by 82% YoY and by 45% from the previous quarter

DVAX's P/B is 77% below its 5-year quarterly average of 12.5 but 12% above its last 4 quarters average of 2.6

Dynavax Technologies's equity has increased by 21% YoY and by 4.8% from the previous quarter

The P/S is 59% less than the 5-year quarterly average of 11.9 but 53% more than the last 4 quarters average of 3.2

DVAX's revenue has dropped by 51% year-on-year and by 21% since the previous quarter

How efficient is Dynavax Technologies business performance

The ROE has plunged by 88% YoY and by 47% from the previous quarter

Dynavax Technologies's return on invested capital has shrunk by 87% YoY and by 45% QoQ

Dynavax Technologies's ROA has plunged by 80% YoY and by 44% from the previous quarter

DVAX's ROS has plunged by 58% YoY and by 26% from the previous quarter

What is DVAX's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for DVAX.

How did Dynavax Technologies financials performed over time

Dynavax Technologies's total assets is 164% higher than its total liabilities

The company's total liabilities fell by 26% YoY but it rose by 2.4% QoQ

DVAX's quick ratio is down by 13% QoQ

Dynavax Technologies's debt is 58% less than its equity

Dynavax Technologies's equity has increased by 21% YoY and by 4.8% from the previous quarter

The debt to equity has contracted by 18% YoY and by 4.5% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.